Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group

Brian M. Alexander, Evanthia Galanis, W. K Alfred Yung, Karla V. Ballman, James M. Boyett, Timothy F. Cloughesy, John F. Degroot, Jason T. Huse, Bhupinder Mann, Warren Mason, Ingo K. Mellinghoff, Tom Mikkelsen, Paul S. Mischel, Brian Patrick O'Neill, Michael D. Prados, Jann N Sarkaria, Abdul Tawab-Amiri, Lorenzo Trippa, Xiaobu Ye, Keith L. LigonDonald A. Berry, Patrick Y. Wen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.

Original languageEnglish (US)
Pages (from-to)180-188
Number of pages9
JournalNeuro-Oncology
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Group Psychotherapy
Clinical Trials
Education
Hope
Brain
Neoplasms
Group Processes
Glioblastoma
Therapeutics

Keywords

  • adaptive randomization
  • biomarkers
  • clinical trials
  • glioblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Alexander, B. M., Galanis, E., Yung, W. K. A., Ballman, K. V., Boyett, J. M., Cloughesy, T. F., ... Wen, P. Y. (2015). Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. Neuro-Oncology, 17(2), 180-188. https://doi.org/10.1093/neuonc/nou154

Brain Malignancy Steering Committee clinical trials planning workshop : Report from the Targeted Therapies Working Group. / Alexander, Brian M.; Galanis, Evanthia; Yung, W. K Alfred; Ballman, Karla V.; Boyett, James M.; Cloughesy, Timothy F.; Degroot, John F.; Huse, Jason T.; Mann, Bhupinder; Mason, Warren; Mellinghoff, Ingo K.; Mikkelsen, Tom; Mischel, Paul S.; O'Neill, Brian Patrick; Prados, Michael D.; Sarkaria, Jann N; Tawab-Amiri, Abdul; Trippa, Lorenzo; Ye, Xiaobu; Ligon, Keith L.; Berry, Donald A.; Wen, Patrick Y.

In: Neuro-Oncology, Vol. 17, No. 2, 01.02.2015, p. 180-188.

Research output: Contribution to journalArticle

Alexander, BM, Galanis, E, Yung, WKA, Ballman, KV, Boyett, JM, Cloughesy, TF, Degroot, JF, Huse, JT, Mann, B, Mason, W, Mellinghoff, IK, Mikkelsen, T, Mischel, PS, O'Neill, BP, Prados, MD, Sarkaria, JN, Tawab-Amiri, A, Trippa, L, Ye, X, Ligon, KL, Berry, DA & Wen, PY 2015, 'Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group', Neuro-Oncology, vol. 17, no. 2, pp. 180-188. https://doi.org/10.1093/neuonc/nou154
Alexander, Brian M. ; Galanis, Evanthia ; Yung, W. K Alfred ; Ballman, Karla V. ; Boyett, James M. ; Cloughesy, Timothy F. ; Degroot, John F. ; Huse, Jason T. ; Mann, Bhupinder ; Mason, Warren ; Mellinghoff, Ingo K. ; Mikkelsen, Tom ; Mischel, Paul S. ; O'Neill, Brian Patrick ; Prados, Michael D. ; Sarkaria, Jann N ; Tawab-Amiri, Abdul ; Trippa, Lorenzo ; Ye, Xiaobu ; Ligon, Keith L. ; Berry, Donald A. ; Wen, Patrick Y. / Brain Malignancy Steering Committee clinical trials planning workshop : Report from the Targeted Therapies Working Group. In: Neuro-Oncology. 2015 ; Vol. 17, No. 2. pp. 180-188.
@article{fa752480152e46c6ba254d28b30c0ee9,
title = "Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group",
abstract = "Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.",
keywords = "adaptive randomization, biomarkers, clinical trials, glioblastoma",
author = "Alexander, {Brian M.} and Evanthia Galanis and Yung, {W. K Alfred} and Ballman, {Karla V.} and Boyett, {James M.} and Cloughesy, {Timothy F.} and Degroot, {John F.} and Huse, {Jason T.} and Bhupinder Mann and Warren Mason and Mellinghoff, {Ingo K.} and Tom Mikkelsen and Mischel, {Paul S.} and O'Neill, {Brian Patrick} and Prados, {Michael D.} and Sarkaria, {Jann N} and Abdul Tawab-Amiri and Lorenzo Trippa and Xiaobu Ye and Ligon, {Keith L.} and Berry, {Donald A.} and Wen, {Patrick Y.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1093/neuonc/nou154",
language = "English (US)",
volume = "17",
pages = "180--188",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Brain Malignancy Steering Committee clinical trials planning workshop

T2 - Report from the Targeted Therapies Working Group

AU - Alexander, Brian M.

AU - Galanis, Evanthia

AU - Yung, W. K Alfred

AU - Ballman, Karla V.

AU - Boyett, James M.

AU - Cloughesy, Timothy F.

AU - Degroot, John F.

AU - Huse, Jason T.

AU - Mann, Bhupinder

AU - Mason, Warren

AU - Mellinghoff, Ingo K.

AU - Mikkelsen, Tom

AU - Mischel, Paul S.

AU - O'Neill, Brian Patrick

AU - Prados, Michael D.

AU - Sarkaria, Jann N

AU - Tawab-Amiri, Abdul

AU - Trippa, Lorenzo

AU - Ye, Xiaobu

AU - Ligon, Keith L.

AU - Berry, Donald A.

AU - Wen, Patrick Y.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.

AB - Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.

KW - adaptive randomization

KW - biomarkers

KW - clinical trials

KW - glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=84924972234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924972234&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nou154

DO - 10.1093/neuonc/nou154

M3 - Article

C2 - 25165194

AN - SCOPUS:84924972234

VL - 17

SP - 180

EP - 188

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 2

ER -